A T-helper 1/interferon- gene signature is prognostic in the adjuvant setting of resectable high-risk melanoma but not in non-small cell lung cancer.
Immune components of the tumor microenvironment (TME) have been associated with disease outcome. We prospectively evaluated the association of an immune-related gene signature (GS) with clinical outcome in melanoma and non-small cell lung cancer (NSCLC) tumor samples from two Phase III studies. The GS was prospectively validated using an adaptive signature design to optimize it for the sample type and technology used in Phase III studies. One-third of the samples were used as "training set"; the remaining two-thirds, constituting the "test set", were used for the prospective validation of the GS. In the melanoma training set, the expression level of eight T-helper (Th1)/interferon (IFN)-γ-related genes in tumor-positive lymph node (LN) tissue predicted the duration of disease-free survival (DFS) and overall survival (OS) in the placebo arm. This GS was prospectively and independently validated as prognostic in the test set. Building a multivariate Cox model in the test set placebo patients from clinical covariates and the GS score, an increased number of melanoma-involved LNs and the GS were associated with DFS and OS. This GS was not associated with DFS in NSCLC, although expression of the Th1/IFN-γ-related genes was associated with the presence of lymphocytes in tumor samples in both indications. These findings provide evidence that expression of Th1/IFN-γ genes in the TME, as measured by this GS, is associated with clinical outcome in melanoma. This suggests that, using this GS, patients with Stage IIIB/C melanoma can be classified into different risk groups.